Abstract
A case is reported of a 21 year old woman who suffered from Castleman's disease and systemic reactive amyloidosis. The serum concentrations of serum amyloid A (SAA) and interleukin 6 (IL-6) were extremely high and amyloid protein was immunohistochemically identified as AA. After surgical excision of a large retroperitoneal lymph node with the pathological findings of plasma cell type of Castleman's disease, both serum SAA and IL-6 declined, showing a similar pattern of reduction curves. All clinical symptoms and laboratory abnormalities greatly improved. The biochemical feature of Castleman's disease is abnormal production of IL-6 and this cytokine continuously may stimulate the synthesis of an amyloid precursor, SAA, causing systemic reactive (AA) amyloidosis. This pathogenetic theory is strongly supported by the present study.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Banks R. E., Forbes M. A., Storr M., Higginson J., Thompson D., Raynes J., Illingworth J. M., Perren T. J., Selby P. J., Whicher J. T. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995 Oct;102(1):217–223. doi: 10.1111/j.1365-2249.1995.tb06659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Beck J. T., Hsu S. M., Wijdenes J., Bataille R., Klein B., Vesole D., Hayden K., Jagannath S., Barlogie B. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994 Mar 3;330(9):602–605. doi: 10.1056/NEJM199403033300904. [DOI] [PubMed] [Google Scholar]
- Castell J. V., Gómez-Lechón M. J., David M., Hirano T., Kishimoto T., Heinrich P. C. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988 May 23;232(2):347–350. doi: 10.1016/0014-5793(88)80766-x. [DOI] [PubMed] [Google Scholar]
- Chan W. C., Hargreaves H., Keller J. Giant lymph node hyperplasia with unusual clinicopathologic features. Cancer. 1984 May 15;53(10):2135–2139. doi: 10.1002/1097-0142(19840515)53:10<2135::aid-cncr2820531024>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
- Frizzera G., Peterson B. A., Bayrd E. D., Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985 Sep;3(9):1202–1216. doi: 10.1200/JCO.1985.3.9.1202. [DOI] [PubMed] [Google Scholar]
- Kazes I., Deray G., Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995 Mar 1;122(5):395–396. doi: 10.7326/0003-4819-122-5-199503010-00024. [DOI] [PubMed] [Google Scholar]
- Ordi J., Grau J. M., Junqué A., Nomdedeu B., Palacin A., Cardesa A. Secondary (AA) amyloidosis associated with Castleman's disease. Report of two cases and review of the literature. Am J Clin Pathol. 1993 Oct;100(4):394–397. doi: 10.1093/ajcp/100.4.394. [DOI] [PubMed] [Google Scholar]
- Perfetti V., Bellotti V., Maggi A., Arbustini E., De Benedetti F., Paulli M., Marinone M. G., Merlini G. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol. 1994 Jul;46(3):189–193. doi: 10.1002/ajh.2830460306. [DOI] [PubMed] [Google Scholar]
- Yoshizaki K., Matsuda T., Nishimoto N., Kuritani T., Taeho L., Aozasa K., Nakahata T., Kawai H., Tagoh H., Komori T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989 Sep;74(4):1360–1367. [PubMed] [Google Scholar]